Oncology
Myelofibrosis
The Multifaceted Targeting of Myelofibrosis: Future Directions
Myelofibrosis is a biologically complex disease driven by multiple mutations, signaling pathways, and interactions between malignant stem and progenitor cells. Emerging strategies are moving beyond JAK inhibition toward combination approaches and alternative target–directed therapies with the goal of balancing disease control and toxicities with symptom relief, all while preventing progression to secondary acute myeloid leukemia (AML).
Myelofibrosis is an extremely complicated disease. We know that mutations in JAK2, CALR, and MPL are the primary driver mutations; however, many patients also have 1 or more other cooperating mutation(s). There may also be multiple subclones, and when a patient with myelofibrosis progresses to secondary AML, that clone may not even harbor the original JAK2 mutation that was present during the chronic myeloproliferative neoplasm stage. How treatment affects this clonal evolution is complex.
There have been positive developments with the 4 available JAK inhibitors (ie, momelotinib, ruxolitinib, fedratinib, and pacritinib) that reinforce JAK2/JAK/STAT signaling as a core driver of this disease. However, none of the US Food and Drug Administration (FDA)–approved drugs for myelofibrosis selectively target JAK2 alone. The impact of these ancillary targets on the efficacy and/or safety of these drugs remains an ongoing question but demonstrates the promise of a multitargeted approach. We are now also moving closer to mutation-specific therapies, particularly for CALR and for compounds with some selectivity for JAK2 V617F. This is exciting for the field.
At the same time, we must be mindful of how novel therapies impact clonal progression, as other pathways can contribute to treatment resistance. For example, with JAK inhibition, escape mechanisms appear to be tied, at least in part, to MAPK signaling. My group is studying one aspect of this signaling axis through RSK1 inhibition. Preclinical data suggest that RSK1 may represent a shared vulnerability across myeloid malignancies, including myelofibrosis and secondary AML.
We are also gaining a deeper appreciation for the interplay between stem and progenitor clones and other cell populations. Myeloid cells, particularly monocytes, secrete inflammatory cytokines (ie, TNF, IL-6, and IL-1) that can act on the progenitor clone, creating bidirectional feedback. There is undoubtedly an important role for these cell populations; whether we should direct therapy toward them is a secondary question.
Despite their promise, the story of combination therapy for myelofibrosis has been complicated. Two drugs, navitoclax and selinexor, have produced impressive spleen responses when combined with ruxolitinib. However, neither combination demonstrated significant improvement in symptom outcomes over ruxolitinib monotherapy. Additionally, their clinical utility has been limited by toxicities (ie, cytopenias and gastrointestinal toxicities, respectively). Pelabresib plus ruxolitinib has also produced substantial spleen responses but has failed to show a significant symptom benefit beyond ruxolitinib monotherapy. The larger point here is that ruxolitinib is quite effective for symptom benefit, which perhaps sets a near-impossible bar for combination therapy. I think that we must be more thoughtful about how future trials are designed, really reconsidering how we evaluate end points from a patient benefit standpoint.
Ultimately, our goals in myelofibrosis management are to prevent disease progression and ameliorate cytopenias, all while providing a symptom relief benefit. However, these outcomes do not necessarily go hand in hand. We need to be thoughtful about when to intervene, which pathways to target, and which patients are most likely to benefit. We would love more target-directed and mutation-specific therapies, but we are still far away from being able to define enough discrete molecular subsets to direct treatment this precisely. The complexity is enormous, but this complexity is also what makes this an exciting area for future investigation.
Bose P, Ali H, Al-Ali HK, et al; SENTRY Trial Investigators. Selinexor plus ruxolitinib in Janus kinase inhibitor-naïve myelofibrosis: phase III SENTRY trial. J Clin Oncol. 2026;44(22):2098-2109. Published correction appears in J Clin Oncol. 2026;44(25):2465.
Celik H, Wass B, Zolotarjova N, et al. Comparison of the enzymatic and cellular profiles of clinical JAK inhibitors for the treatment of myelofibrosis. Blood Neoplasia. 2026;3(2):100206. doi:10.1016/j.bneo.2026.100206
ClinicalTrials.gov. Therapeutic RSK1 targeting in myelofibrosis. Updated October 21, 2026. Accessed October 28, 2026. https://clinicaltrials.gov/study/NCT07379125
Fisher DAC, Miner CA, Engle EK, et al. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling. Leukemia. 2019;33(8):1978-1995. doi:10.1038/s41375-019-0379-y
Grinfeld J, Nangalia J, Baxter EJ, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379(15):1416-1430. doi:10.1056/NEJMoa1716614
Kong T, Laranjeira ABA, Letson CT, et al. RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia. Nat Commun. 2025;16(1):492. doi:10.1038/s41467-024-55643-7
Kong T, Laranjeira ABA, Yang K, et al. DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression. Nat Cancer. 2023;4(1):108-127. doi:10.1038/s43018-022-00486-8
Loscocco GG, Guglielmelli P. Targeted therapies in myelofibrosis: present landscape, ongoing studies, and future perspectives. Am J Hematol. 2025;100(suppl 4):30-50. doi:10.1002/ajh.27658
Pemmaraju N, Mead AJ, Somervaille TCP, et al. TRANSFORM-1 phase 3 study: efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis. Blood. 2026;148(16):2029-2042. doi:10.1182/blood.2025032360
Rampal RK, Grosicki S, Chraniuk D, et al. Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial. Nat Med. 2025;31(5):1531-1538. doi:10.1038/s41591-025-03572-3



